Maurizio Marogna

Maurizio Marogna

Others, Allergy Unit , Macchi Hospital Foundation,
Varese
Italy

Publications
  • Review Article
    Sublingual Immunotherapy in Real-Life: When and Why

    Author(s): Maurizio Marogna*Maurizio Marogna*

    Sublingual immunotherapy (SLIT) has gained wide acceptance in many European countries and has raised the level of interest in immunotherapy among practicing allergists and primary care physicians. SLIT was firstly accepted as a viable alternative to subcutaneous immunotherapy (SCIT) in the World Health Organization (WHO) Position Paper, published in 1998, and then included in ARIA guidelines. Since 1986, 60 DBPC-RCT trials have been published. There seem to be 2 distinct and perhaps sequential immunologic responses to SLIT; generation of regulatory T- cells (Tregs) secreting interleukin (IL)-10 and transforming growth factor (TGF)-β and immune deviation from Th2 to Th1 responses. The available meta-analyses are in favor of SLIT (rhinitis and asthma in adults and children).SLIT appears to be better tolerated than SCIT: a few case of SLIT-related anaphylaxis have been reported but .. View More»
    DOI: 10.4172/2155-6121.1000107

    Abstract